New study tests fatigue fighter for advanced breast cancer patients
NCT ID NCT07543536
First seen Apr 23, 2026 · Last updated May 22, 2026 · Updated 8 times
Summary
This study tests whether megestrol acetate, a drug that may help with fatigue, can prevent or reduce tiredness in people with advanced breast cancer who are starting a treatment called trastuzumab deruxtecan. About 132 women aged 18-75 with HER2-positive, low, or ultralow breast cancer will take either megestrol acetate or a placebo. The goal is to see if this approach improves their quality of life by easing fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun yat-Sen University Cancer Center
Guangzhou, Yuexiu District, 510060, China
Conditions
Explore the condition pages connected to this study.